Why Illumina’s latest quarter has put the stock back in focus

Illumina (ILMN) has drawn investor attention after reporting fourth quarter and full year 2025 results that showed stronger profitability, 20% growth in clinical consumables outside China, and fresh guidance that incorporates the SomaLogic acquisition.

The recent 1 day share price return of 2.07% to US$116.81 comes after earnings, new 2026 guidance and an ongoing buyback program that has retired 6.31% of shares. However, the 30 day share price return of 17.54% and 3 year total shareholder return of 40.74% suggest momentum has been mixed over different timeframes.

If Illumina’s latest quarter has you thinking more broadly about genomics and data heavy healthcare, it could be a good moment to scan our 25 healthcare AI stocks as potential next ideas to research.

With Illumina trading at US$116.81, a 1 year total return of 15.55% but a 5 year total return of 74.13% and an indicated intrinsic discount of about 22%, you have to ask yourself: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 14.1% Undervalued

Illumina’s most followed narrative points to a fair value of about $135.94 per share versus the last close at $116.81. This puts the spotlight on its earnings power and capital allocation plans.

Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements. Further scaling, along with tax headwinds turning into tailwinds, sets the stage for continued net margin and earnings growth over the next several years.

Want the full story behind that valuation gap? The narrative leans on steady revenue progress, margin resets, and a richer earnings multiple than today. Curious how those pieces fit together and what that implies for long term returns? The detailed assumptions sit inside that fair value.

Result: Fair Value of $135.94 (UNDERVALUED)

However, risks around tighter research budgets and ongoing regulatory uncertainty in China could still derail those assumptions and reset expectations for Illumina’s earnings power.

Next Steps

If this mix of enthusiasm and caution resonates with you, this may be a good time to review the underlying data yourself and consider both sides. You can then round out your view by checking the 4 key rewards and 1 important warning sign.

Ready to find your next idea?

If this update on Illumina has sharpened your thinking, now is the time to broaden your watchlist and line up a few fresh candidates to research.

• Target resilience by checking companies that pass our balance sheet and fundamentals filters using the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for value by reviewing our 55 high quality undervalued stocks that flag companies with strong fundamentals trading below their estimated worth.
• Spot potential early movers with our screener containing 24 high quality undiscovered gems before they land on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.